Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
6
×
boston blog main
boston top stories
drugs
6
×
fda
6
×
life sciences
national blog main
national top stories
clinical trials
new york blog main
new york top stories
alnylam pharmaceuticals
biotech
patisiran
san diego blog main
san diego top stories
akcea therapeutics
hereditary transthyretin amyloidosis
inotersen
onpattro
paul matteis
rna interference
san francisco blog main
san francisco top stories
tafamidis
acute hepatic porphyrias
akin akinc
allopregnanolone
aminolevulinic acid
antibiotics
arvinas
astrazeneca
barry greene
boston university
boulder/denver
boulder/denver blog main
boulder/denver top stories
brexanolone
carbapenem-resistant enterobacteriaceae
celgene
What
fda
medicine
alnylam
drug
rna
ago
interference
make
pharmaceuticals
rnai
uses
way
approval
approve
approved
approves
awaits
biological
biotechs
brexanolone
cells
cf
chose
close
company
crisis
crossed
cystic
decades
decision
depression
devastating
developer
device
discovered
disorder
ema
employ
europe
fast
Language
unknown
Current search:
fda
×
drugs
×
boston
×
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision